Karyopharm's Partner Antengene Receives Priority Review For Selinexor Application In China

Karyopharm Therapeutics Inc's (NASDAQ: KPTI) collaborating partner Antengene Corporation Limited has received priority review from China's National Medical Products Administration (NMPA) for ATG-010 (selinexor, XPOVIO). It is a first-in-class selective inhibitor of nuclear export (SINE) compound to treat patients with relapsed/refractory multiple myeloma (rrMM).
The FDA has approved ATG-010 (selinexor) for three indications within 18 months, including relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma.
Selinexor is also being evaluated in the Phase 3 SIENDO trial in patients with endometrial cancer. Topline data expected in the second half of 2021.
Price Action: KPTI closed 2.2% lower at $14.59 on Tuesday.